AI in equity analysis reveals growth opportunities and risk factors for small- and mid-cap tech and healthcare companies, enhancing investment decisions.
Sector-specific Forecast Models reveal how tech, pharma, biotech, and energy industries achieve accurate predictions and strategic planning.
Veränderungen im Zinsumfeld wirken sich auf Small-Cap-Wachstumsaktien aus, indem sie die Kreditkosten, Bewertungen und Anlagemöglichkeiten beeinflussen.
Small- and mid-cap stocks face unique risks from liquidity, free float, and trading volume, affecting volatility, trading costs, and price stability.
ESG equity analysis reveals key risks, opportunities, and valuation impacts for tech, pharma, and energy small-cap stocks.
Independent equity research for small and mid caps offers unbiased analysis, broader coverage, and deeper insights than traditional bank research.
Biotech stocks in the small- and mid-cap segment require unique valuation methods like rNPV, DCF, and pipeline analysis to assess risk and growth potential.
Analyze small-cap pharma companies by reviewing pipelines, patent strength, and regulatory risks to identify growth opportunities and potential red flags.
EU Drug Pricing in 2025 faces new HTA rules, harmonised assessments, and ongoing national pricing control, shaping market access and pharma strategy.
Analyze a Biotech Stock in 2025 by evaluating pipeline, catalysts, and cash runway to identify growth potential, manage risk, and make informed investment decisions.